Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib ...

Melanoma in adolescents and young adults (AYAs) has distinct epidemiologic characteristics, with a declining incidence over the past 2 decades but an increasing trend in all-cause and cancer-specific ...

Adding tilsotolimod to ipilimumab did not improve response or survival outcomes in patients with advanced melanoma.

During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic melanoma ...

Cancer-associated fibroblasts (CAFs) play an important role in metastatic melanoma, and an enhanced understanding of that role could lead to important new therapeutic pathways, according to a new ...

After being diagnosed with advanced stage melanoma, Tash Sutton is on a mission to help others avoid the same fate.

Rick Schneider is a family man — a husband and doting father to three girls. He’s also an outdoorsman who loves to bike, hike ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, ...

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster ... which enrolled people with stage III-IV melanoma that had been completely surgically removed.

Tim Story, a Mississippi football coach, was given months to live after late-stage colon cancer. He enrolled in a clinical ...

BMS said that this is the first regimen showing a statistical benefit over PD-1 monotherapy such as Opdivo (nivolumab) in metastatic melanoma, which has become established as standard of care in ...

This trial, ILLUMIATE-301 (NCT03445533), included 481 adults with unresectable, stage III-IV melanoma who had at least 1 measurable lesion accessible for injection and had confirmed progression ...